Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action-- DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action-- DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA ® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing -- -- International Strategy
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA ® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing -- -- International Strategy